CHCWM – Cancer & Hematology Centers of West Michigan

(SL03-OHD-105) Shattuck

Description: An Open-Label, Phase 1B Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Pegylated Liposomal Doxorubicin or Paclitaxel to Subjects with Platinum-Resistant Gynecological Cancers

Mechanism of Action:  SL172154 Blocks antiphagocytic signal on cancer cells by attaching to SIRP alpha (receptor for CD47) and simultaneously engages costimulatory CD40L

Target Patient Population:  High grade ovarian, primary peritoneal or fallopian tube cancers.

Study Design:  Drug is given IV Day 1 and 8 of a 28 day cycle.  Pegylated Liposomal Doxorubicin is given Standard of Care schedule